The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.
An article from
Obesity drugs
The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.
Published July 23, 2026
Eli Lilly will file an approval application for its weight loss drug retatrutide in the first quarter of 2027.
Eli Lilly reports positive Phase 3 data for retatrutide, showing major weight loss in adults. US regulatory submission is planned…
Retatrutide, the obesity candidate that has shown the most powerful weight loss in late-stage trials, will be filed for approval…
Eli Lilly said Thursday that its triple agonist retatrutide allowed obesity patients to lose about a quarter of their weight…
There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its…
Eli Lilly says retatrutide helped obesity trial participants lose up to 28.3% body weight in the Phase 3 TRIUMPH-1 study.
Eli Lilly's new obesity drug retatrutide shows remarkable results. In a major trial, patients lost up to 30% of their body…
Eli Lilly Says Retatrutide Shows Cardiovascular, Diabetic Benefits - Eli Lilly (NYSE:LLY)
Updated: Lilly's triple agonist heads to regulators after two more Phase 3 obesity wins
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit
Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average
